Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy

Wang, Hongyun; Sun, Guodong; Zhang, Zhigang; Ou, Yang

doi:10.1016/j.biopha.2017.04.104

Cited by 30 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 Higher cell inhibition ability observed by I/ D-LPNs than free I/D (P < 0.05) indicated that the LPNs might have the enhanced ability to adhere to the cell membrane due to the similar nature of the lipids and the cell membrane. 43 Blank LPNs did not show any cytotoxicity compared with control, indicating the safety and biocompatibility of the materials used for the preparation of the LPNs. 44 The biocompatibility of LPNs is consistent with previous findings on LPNs and proved that this nano-system can be safely used as a drug/gene delivery vehicle.…”

Section: In Vitro Drug and Gene Releasementioning

confidence: 86%

Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

View full text Add to dashboard Cite

Background: The current approach for treating colorectal cancer favors the use of drug and gene combination therapy, and targeted nano-systems are gaining considerable attention for minimizing toxicity and improving the efficacy of anticancer treatment. The aim of this study was to develop ligand-modified, irinotecan and gene co-loaded lipid-polymer hybrid nanocarriers for targeted colorectal cancer combination therapy. Methods: Hyaluronic acid modified, irinotecan and gene co-loaded LPNs (HA-I/D-LPNs) were prepared using a solvent-evaporation method. Their average size, zeta potential, drug and gene loading capacity were characterized. The in vitro and in vivo gene transfection and anti-tumor ability of this nano-system were evaluated on colorectal cancer cells and mice bearing colorectal cancer model. Results: HA-I/D-LPNs had a size of 182.3 ± 5.1, over 80% drug encapsulation efficiency and over 90% of gene loading capacity. The peak plasma concentration (C max) and half-life (T 1/2) achieved from HA-I/D-LPNs were 41.31 ± 1.58 μg/mL and 12.56 ± 0.67 h. HA-I/ D-LPNs achieved the highest tumor growth inhibition efficacy and the most prominent transfection efficiency in vivo. Conclusion: HA-I/D-LPNs exhibited the most remarkable tumor inhibition efficacy and best gene transfection efficiency in the tumor, which could prove the effects of the drug and gene combination therapy.

show abstract

Section: In Vitro Drug and Gene Releasementioning

confidence: 86%

Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

View full text Add to dashboard Cite

show abstract

“…The improved activity and penetration of drugs delivered with NAcGal modified LNPs can be made use of to improve the efficacy of the standard drug dose, attenuate side effects, and overcome drug resistance. 29 …”

Section: Discussionmentioning

confidence: 99%

“…Intracellular accumulation assay was used on HepG2 cells to quantitatively determine the cellular uptake of the LNPs. 29 Coumarin 6 (C6) was applied as a model fluorescent molecule and was loaded into the LNPs by adding C6 to the oil phase during the preparation of the LNPs. After cells were equilibrated with Hank’s buffered salt solution (HBSS) at 37°C for 1 hour, C6 loaded LNPs were added at concentrations of 200 mg/mL, respectively.…”

Section: Methodsmentioning

confidence: 99%

Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib

Duan¹,

Liu²

2018

DDDT

View full text Add to dashboard Cite

PurposeTargeted hepatocellular carcinoma therapy was carried out to improve the efficacy of liver cancer treatment. The purpose of this study was to design an N-acetylgalactosamine (NAcGal) modified and pH sensitive doxorubicin (DOX) prodrug (NAcGal-DOX) for the construction of lipid nanoparticles (LNPs).MethodsNAcGal-DOX and sorafenib (SOR) co-loaded LNPs were designed and the synergistic effects were evaluated on human hepatic carcinoma (HepG2) cells in vitro and anti-hepatic carcinoma mice model in vivo.ResultsCellular uptake efficiency of NAcGal modified LNPs was significantly higher than unmodified LNPs. NAcGal modified LNPs showed the most significant inhibition effect among all the samples tested. The results revealed that the LNPs system achieved significant synergistic effects, best tumor inhibition ability and the lowest systemic toxicity.ConclusionThese results proved that the NAcGal conjugated and pH sensitive co-delivery nano-system could be a promising strategy for treatment of hepatocellular carcinoma.

show abstract

“…45 The tumor tissue concentrations of LPNs kept up high at 24 h post administration, indicating the sustained-release behavior of the LPNs, which may attribute to the presence of PEG chain on the surface of particles. 46 The most significant in vivo tumor inhibition efficiency was observed when FA-CBP/PTX-LPNs formula was administrated (Figure 7), which was better than FA-CBP-LPNs (P < 0.05) and CBP/PTX-LPNs (P < 0.01). CBP/ PTX-LPNs illustrated better antitumor ability than free CBP/PTX (P < 0.01), the latter showed remarkable ability over the control group (P < 0.05).…”

Section: In Vivo Tissue Distribution and Anticancer Ability Of Lpnsmentioning

confidence: 93%

Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles

Wang¹

2020

DDDT

View full text Add to dashboard Cite

Purpose: Cervical cancer is one of the most common causes of death among women globally. Combinations of cisplatin, paclitaxel, bevacizumab, carboplatin, topotecan, and gemcitabine are recommended as first-line therapies. Methods: This study focuses on the development of folate-decorated, pH-sensitive lipidpolymer hybrid nanoparticles (LPNs). Loading carboplatin (CBP) and paclitaxel (PTX), LPNs were expected to combine the therapeutic effects of CBP and PTX, thus show synergistic ability on cervical cancer. Results: FA-CBP/PTX-LPNs showed the sizes of 169.9 ± 5.6 nm, with a narrow size distribution of 0.151 ± 0.023. FA-CBP/PTX-LPNs exhibited pH-responsive drug release, high cellular uptake efficiency (66.7 ± 3.1%), and prominent cell inhibition capacity (23 ± 1.1%). In vivo tumor distribution and tumor inhibition efficiency of FA-CBP/PTX-LPNs was the highest, with no obvious body weight lost. Conclusion: High tumor distribution and remarkable antitumor efficiency obtained using in vitro as well as in vivo models further proved the FA-CBP/PTX-LPNs is a promising tool for cervical cancer therapy.

show abstract

Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy

Cited by 30 publications

References 44 publications

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib

<p>Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles</p>

Contact Info

Product

Resources

About